| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunotherapy, Adoptive | 29 | 2023 | 1860 | 2.890 |
Why?
|
| CD8-Positive T-Lymphocytes | 29 | 2024 | 1656 | 2.870 |
Why?
|
| Antigens, Neoplasm | 25 | 2021 | 1581 | 2.740 |
Why?
|
| Interleukins | 8 | 2020 | 339 | 2.150 |
Why?
|
| T-Lymphocytes | 27 | 2024 | 3946 | 1.840 |
Why?
|
| Epitopes, T-Lymphocyte | 11 | 2024 | 225 | 1.780 |
Why?
|
| Melanoma | 29 | 2023 | 5596 | 1.740 |
Why?
|
| T-Lymphocytes, Cytotoxic | 18 | 2020 | 1019 | 1.650 |
Why?
|
| Adoptive Transfer | 8 | 2019 | 431 | 1.470 |
Why?
|
| Receptors, Antigen, T-Cell | 13 | 2023 | 1136 | 1.460 |
Why?
|
| Immunologic Memory | 6 | 2021 | 376 | 1.210 |
Why?
|
| Immunotherapy | 20 | 2024 | 3561 | 1.120 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 15 | 2023 | 1033 | 1.100 |
Why?
|
| Carcinoma, Merkel Cell | 3 | 2024 | 172 | 0.990 |
Why?
|
| Neoplasms | 31 | 2024 | 15951 | 0.940 |
Why?
|
| Polyomavirus | 1 | 2024 | 37 | 0.930 |
Why?
|
| Cellular Microenvironment | 2 | 2021 | 36 | 0.880 |
Why?
|
| Epitopes | 7 | 2021 | 699 | 0.870 |
Why?
|
| CD28 Antigens | 5 | 2020 | 212 | 0.820 |
Why?
|
| CTLA-4 Antigen | 3 | 2016 | 678 | 0.810 |
Why?
|
| T-Lymphocyte Subsets | 9 | 2019 | 587 | 0.760 |
Why?
|
| Lymphocyte Activation | 17 | 2021 | 1719 | 0.710 |
Why?
|
| OX40 Ligand | 1 | 2020 | 23 | 0.700 |
Why?
|
| Cell Differentiation | 4 | 2021 | 4105 | 0.700 |
Why?
|
| Cell Hypoxia | 1 | 2021 | 353 | 0.700 |
Why?
|
| Mass Spectrometry | 1 | 2021 | 721 | 0.650 |
Why?
|
| Tumor Microenvironment | 17 | 2024 | 3054 | 0.640 |
Why?
|
| Liposarcoma, Myxoid | 3 | 2021 | 38 | 0.620 |
Why?
|
| Skin Neoplasms | 7 | 2024 | 4893 | 0.590 |
Why?
|
| Cell- and Tissue-Based Therapy | 3 | 2023 | 382 | 0.570 |
Why?
|
| Cancer Vaccines | 7 | 2021 | 759 | 0.560 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2020 | 617 | 0.550 |
Why?
|
| CD4-Positive T-Lymphocytes | 10 | 2018 | 1044 | 0.540 |
Why?
|
| Membrane Proteins | 7 | 2021 | 2922 | 0.530 |
Why?
|
| Nanog Homeobox Protein | 4 | 2020 | 62 | 0.510 |
Why?
|
| T-Lymphocytes, Regulatory | 6 | 2018 | 704 | 0.510 |
Why?
|
| Humans | 111 | 2024 | 270709 | 0.490 |
Why?
|
| Neoplasm Proteins | 10 | 2014 | 3345 | 0.480 |
Why?
|
| Cell Line, Tumor | 28 | 2024 | 14885 | 0.470 |
Why?
|
| Killer Cells, Natural | 7 | 2019 | 967 | 0.460 |
Why?
|
| Histocompatibility Antigens Class I | 5 | 2019 | 246 | 0.460 |
Why?
|
| Tumor Escape | 4 | 2021 | 247 | 0.440 |
Why?
|
| Cytotoxicity Tests, Immunologic | 3 | 2005 | 85 | 0.430 |
Why?
|
| Antigens | 2 | 2012 | 279 | 0.430 |
Why?
|
| Ipilimumab | 2 | 2023 | 772 | 0.420 |
Why?
|
| Carcinoma, Pancreatic Ductal | 5 | 2020 | 1831 | 0.420 |
Why?
|
| MART-1 Antigen | 10 | 2021 | 113 | 0.420 |
Why?
|
| Antineoplastic Agents, Immunological | 5 | 2020 | 1337 | 0.410 |
Why?
|
| Dendritic Cells | 5 | 2021 | 1104 | 0.400 |
Why?
|
| Antigens, Surface | 2 | 2013 | 304 | 0.400 |
Why?
|
| Cytotoxicity, Immunologic | 8 | 2021 | 691 | 0.400 |
Why?
|
| Pancreatic Neoplasms | 5 | 2020 | 5258 | 0.390 |
Why?
|
| Receptors, Immunologic | 4 | 2019 | 310 | 0.370 |
Why?
|
| Sarcoma, Synovial | 3 | 2021 | 141 | 0.360 |
Why?
|
| Precision Medicine | 2 | 2019 | 1216 | 0.340 |
Why?
|
| Chondrosarcoma | 1 | 2012 | 213 | 0.340 |
Why?
|
| Genetic Techniques | 1 | 2010 | 150 | 0.330 |
Why?
|
| Nanofibers | 2 | 2024 | 22 | 0.330 |
Why?
|
| Lymphocyte Depletion | 2 | 2021 | 316 | 0.330 |
Why?
|
| Nephritis, Interstitial | 2 | 2021 | 60 | 0.330 |
Why?
|
| Interferon-gamma | 5 | 2020 | 1169 | 0.300 |
Why?
|
| Adjuvants, Immunologic | 2 | 2016 | 669 | 0.300 |
Why?
|
| Neoplastic Stem Cells | 4 | 2020 | 1456 | 0.300 |
Why?
|
| Animals | 38 | 2024 | 61350 | 0.290 |
Why?
|
| Immunophenotyping | 3 | 2019 | 1723 | 0.280 |
Why?
|
| Cell Proliferation | 8 | 2024 | 7233 | 0.270 |
Why?
|
| Peptides | 5 | 2024 | 1502 | 0.270 |
Why?
|
| Forkhead Transcription Factors | 2 | 2009 | 762 | 0.270 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2012 | 1347 | 0.270 |
Why?
|
| Antigens, CD | 4 | 2019 | 1420 | 0.270 |
Why?
|
| Azacitidine | 2 | 2012 | 1218 | 0.260 |
Why?
|
| Cell Line | 8 | 2021 | 5313 | 0.260 |
Why?
|
| Genetic Engineering | 3 | 2019 | 288 | 0.260 |
Why?
|
| Programmed Cell Death 1 Receptor | 4 | 2020 | 1096 | 0.250 |
Why?
|
| Cross-Priming | 3 | 2013 | 40 | 0.240 |
Why?
|
| Mice | 23 | 2024 | 35420 | 0.240 |
Why?
|
| Monophenol Monooxygenase | 5 | 2005 | 60 | 0.230 |
Why?
|
| Acute Kidney Injury | 2 | 2022 | 758 | 0.230 |
Why?
|
| Vidarabine | 1 | 2009 | 1384 | 0.230 |
Why?
|
| HLA-A2 Antigen | 5 | 2017 | 172 | 0.220 |
Why?
|
| Pancreas | 2 | 2020 | 737 | 0.220 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 3 | 2014 | 56 | 0.220 |
Why?
|
| CD3 Complex | 3 | 2012 | 321 | 0.220 |
Why?
|
| Histocompatibility Antigens | 1 | 2003 | 79 | 0.210 |
Why?
|
| Vaccines, Synthetic | 2 | 2011 | 325 | 0.210 |
Why?
|
| Biocompatible Materials | 2 | 2014 | 202 | 0.210 |
Why?
|
| Clone Cells | 8 | 2013 | 589 | 0.210 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2022 | 59 | 0.200 |
Why?
|
| Nephritis | 1 | 2022 | 41 | 0.200 |
Why?
|
| Melanocytes | 2 | 2017 | 240 | 0.200 |
Why?
|
| Infliximab | 2 | 2021 | 138 | 0.200 |
Why?
|
| Cancer-Associated Fibroblasts | 1 | 2023 | 116 | 0.190 |
Why?
|
| Major Histocompatibility Complex | 1 | 2021 | 99 | 0.190 |
Why?
|
| Interleukin-6 | 4 | 2022 | 1032 | 0.190 |
Why?
|
| Histamine | 1 | 2021 | 58 | 0.190 |
Why?
|
| Genomics | 3 | 2022 | 2833 | 0.190 |
Why?
|
| Cytokines | 6 | 2019 | 2803 | 0.190 |
Why?
|
| Coculture Techniques | 4 | 2021 | 626 | 0.190 |
Why?
|
| Stomach Neoplasms | 2 | 2024 | 2339 | 0.190 |
Why?
|
| Vitiligo | 1 | 2000 | 17 | 0.190 |
Why?
|
| Male | 25 | 2021 | 128479 | 0.180 |
Why?
|
| Transfection | 3 | 2004 | 3109 | 0.180 |
Why?
|
| T-Cell Antigen Receptor Specificity | 2 | 2014 | 92 | 0.180 |
Why?
|
| Adenocarcinoma | 5 | 2024 | 7920 | 0.180 |
Why?
|
| Histiocytes | 1 | 2020 | 94 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2020 | 126 | 0.170 |
Why?
|
| Immunity | 2 | 2020 | 352 | 0.170 |
Why?
|
| Interleukin-15 | 1 | 2021 | 197 | 0.170 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 2 | 2012 | 104 | 0.170 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 209 | 0.170 |
Why?
|
| CREB-Binding Protein | 1 | 2020 | 97 | 0.170 |
Why?
|
| Epigenesis, Genetic | 3 | 2018 | 1439 | 0.170 |
Why?
|
| Receptors, CXCR5 | 1 | 2019 | 29 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 16750 | 0.160 |
Why?
|
| Colitis | 1 | 2022 | 340 | 0.160 |
Why?
|
| Female | 32 | 2021 | 148873 | 0.160 |
Why?
|
| Middle Aged | 20 | 2021 | 90517 | 0.160 |
Why?
|
| Mitochondrial ADP, ATP Translocases | 1 | 2018 | 6 | 0.160 |
Why?
|
| Cell Self Renewal | 1 | 2019 | 69 | 0.160 |
Why?
|
| Mitochondrial Proton-Translocating ATPases | 1 | 2018 | 23 | 0.160 |
Why?
|
| gp100 Melanoma Antigen | 5 | 2017 | 94 | 0.160 |
Why?
|
| Cell Separation | 4 | 2012 | 606 | 0.160 |
Why?
|
| Receptors, CCR7 | 3 | 2007 | 38 | 0.160 |
Why?
|
| Transforming Growth Factor beta | 2 | 2021 | 1105 | 0.160 |
Why?
|
| Myasthenia Gravis | 1 | 2019 | 106 | 0.160 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2020 | 191 | 0.160 |
Why?
|
| Drug Implants | 1 | 2018 | 52 | 0.160 |
Why?
|
| Gene Products, env | 1 | 2018 | 36 | 0.150 |
Why?
|
| B7 Antigens | 1 | 2019 | 85 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2020 | 538 | 0.150 |
Why?
|
| Enterocolitis | 1 | 2018 | 48 | 0.150 |
Why?
|
| Lymphoma | 3 | 2020 | 1516 | 0.150 |
Why?
|
| Mice, Inbred NOD | 5 | 2020 | 896 | 0.150 |
Why?
|
| Combined Modality Therapy | 6 | 2022 | 9054 | 0.150 |
Why?
|
| Myocarditis | 1 | 2020 | 177 | 0.150 |
Why?
|
| Transcriptome | 3 | 2024 | 1960 | 0.150 |
Why?
|
| Mice, Inbred C57BL | 9 | 2021 | 7053 | 0.150 |
Why?
|
| Natural Killer T-Cells | 1 | 2019 | 117 | 0.150 |
Why?
|
| B7-H1 Antigen | 2 | 2022 | 1098 | 0.150 |
Why?
|
| Gastrointestinal Agents | 1 | 2018 | 119 | 0.150 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2019 | 201 | 0.150 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 2018 | 109 | 0.150 |
Why?
|
| Histone Deacetylases | 1 | 2020 | 362 | 0.150 |
Why?
|
| Histone Deacetylase 1 | 1 | 2017 | 62 | 0.150 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2020 | 525 | 0.150 |
Why?
|
| Computer Simulation | 1 | 2023 | 1569 | 0.140 |
Why?
|
| Cells, Cultured | 5 | 2020 | 5658 | 0.140 |
Why?
|
| Simian Immunodeficiency Virus | 1 | 2018 | 134 | 0.140 |
Why?
|
| CRISPR-Cas Systems | 1 | 2021 | 362 | 0.140 |
Why?
|
| Membrane Glycoproteins | 5 | 2013 | 1091 | 0.140 |
Why?
|
| Immunomodulation | 1 | 2019 | 253 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2018 | 134 | 0.140 |
Why?
|
| Disease Models, Animal | 4 | 2022 | 7323 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2018 | 209 | 0.140 |
Why?
|
| Vaccinia virus | 1 | 1996 | 78 | 0.140 |
Why?
|
| Precancerous Conditions | 1 | 2023 | 1061 | 0.140 |
Why?
|
| Remission Induction | 2 | 2016 | 3658 | 0.140 |
Why?
|
| Drug Resistance, Multiple | 1 | 2017 | 221 | 0.140 |
Why?
|
| Oligopeptides | 1 | 1999 | 450 | 0.140 |
Why?
|
| Tumor Cells, Cultured | 7 | 2019 | 5759 | 0.140 |
Why?
|
| Mice, SCID | 5 | 2020 | 1825 | 0.130 |
Why?
|
| Flow Cytometry | 8 | 2018 | 3040 | 0.130 |
Why?
|
| Disease Progression | 3 | 2024 | 6880 | 0.130 |
Why?
|
| Macaca mulatta | 1 | 2018 | 690 | 0.130 |
Why?
|
| AIDS Vaccines | 1 | 2016 | 66 | 0.130 |
Why?
|
| Membrane Transport Proteins | 1 | 2017 | 248 | 0.130 |
Why?
|
| Cyclophosphamide | 2 | 2021 | 3246 | 0.130 |
Why?
|
| Cyclin D1 | 1 | 2018 | 591 | 0.130 |
Why?
|
| Merkel cell polyomavirus | 2 | 2014 | 31 | 0.130 |
Why?
|
| RNA, Small Interfering | 2 | 2018 | 2192 | 0.120 |
Why?
|
| Exosomes | 1 | 2018 | 255 | 0.120 |
Why?
|
| Rituximab | 1 | 2020 | 1594 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2012 | 3582 | 0.120 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2018 | 563 | 0.120 |
Why?
|
| Cell Communication | 2 | 2014 | 509 | 0.120 |
Why?
|
| Nuclear Proteins | 2 | 2018 | 3435 | 0.120 |
Why?
|
| Immunologic Capping | 1 | 2014 | 7 | 0.120 |
Why?
|
| Electrochemistry | 1 | 2014 | 38 | 0.120 |
Why?
|
| Adult | 15 | 2021 | 82042 | 0.120 |
Why?
|
| Self Tolerance | 1 | 2014 | 18 | 0.120 |
Why?
|
| HLA Antigens | 2 | 2012 | 593 | 0.120 |
Why?
|
| Virus Replication | 1 | 2018 | 762 | 0.120 |
Why?
|
| Silicon | 1 | 2014 | 48 | 0.120 |
Why?
|
| Aged | 14 | 2021 | 73601 | 0.110 |
Why?
|
| Drug Delivery Systems | 1 | 2018 | 663 | 0.110 |
Why?
|
| Electronics, Medical | 1 | 2013 | 16 | 0.110 |
Why?
|
| Renal Dialysis | 1 | 2021 | 901 | 0.110 |
Why?
|
| Lymphocyte Count | 3 | 2005 | 485 | 0.110 |
Why?
|
| Neoplasms, Second Primary | 1 | 2022 | 1388 | 0.110 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2014 | 242 | 0.110 |
Why?
|
| Models, Immunological | 1 | 2013 | 79 | 0.110 |
Why?
|
| Nanostructures | 1 | 2014 | 100 | 0.110 |
Why?
|
| Pyridines | 2 | 2018 | 1310 | 0.110 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2019 | 1002 | 0.110 |
Why?
|
| Staining and Labeling | 2 | 2008 | 443 | 0.110 |
Why?
|
| Alcohols | 1 | 2012 | 24 | 0.100 |
Why?
|
| WT1 Proteins | 1 | 2013 | 107 | 0.100 |
Why?
|
| Breast Neoplasms | 4 | 2020 | 16243 | 0.100 |
Why?
|
| Magnetite Nanoparticles | 1 | 2012 | 53 | 0.100 |
Why?
|
| Metal Nanoparticles | 1 | 2014 | 162 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 4 | 2018 | 4470 | 0.100 |
Why?
|
| Lymphocytes | 2 | 2014 | 1273 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 2 | 2019 | 2396 | 0.100 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2011 | 59 | 0.100 |
Why?
|
| Immunity, Cellular | 2 | 2005 | 436 | 0.100 |
Why?
|
| HIV-1 | 1 | 2016 | 636 | 0.100 |
Why?
|
| DNA Primers | 2 | 2012 | 1489 | 0.100 |
Why?
|
| Glioblastoma | 1 | 2022 | 1781 | 0.100 |
Why?
|
| Mitochondria | 1 | 2018 | 1293 | 0.090 |
Why?
|
| Prostheses and Implants | 1 | 2013 | 291 | 0.090 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2014 | 622 | 0.090 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2018 | 1404 | 0.090 |
Why?
|
| Glioma | 1 | 2022 | 1986 | 0.090 |
Why?
|
| Antineoplastic Agents | 3 | 2014 | 14639 | 0.090 |
Why?
|
| Interleukin-1 | 1 | 2012 | 472 | 0.090 |
Why?
|
| Cell Culture Techniques | 1 | 2013 | 574 | 0.090 |
Why?
|
| Immunity, Innate | 1 | 2014 | 697 | 0.090 |
Why?
|
| Polyomavirus Infections | 1 | 2011 | 147 | 0.090 |
Why?
|
| Apoptosis | 4 | 2017 | 7757 | 0.090 |
Why?
|
| DNA-Binding Proteins | 2 | 2020 | 4992 | 0.090 |
Why?
|
| Autoimmunity | 1 | 2012 | 263 | 0.090 |
Why?
|
| Macrophages | 3 | 2022 | 1334 | 0.090 |
Why?
|
| Leukemia | 4 | 2013 | 1719 | 0.090 |
Why?
|
| Tumor Virus Infections | 1 | 2011 | 248 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2024 | 3929 | 0.090 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2017 | 1336 | 0.090 |
Why?
|
| Neoplasm Metastasis | 3 | 2016 | 5332 | 0.090 |
Why?
|
| Treatment Outcome | 8 | 2023 | 33847 | 0.090 |
Why?
|
| Liver | 1 | 2019 | 3058 | 0.080 |
Why?
|
| Biomedical Research | 1 | 2016 | 799 | 0.080 |
Why?
|
| Lung Neoplasms | 2 | 2023 | 12041 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2024 | 9048 | 0.080 |
Why?
|
| Piperazines | 1 | 2018 | 2142 | 0.080 |
Why?
|
| Cell Division | 3 | 2007 | 2657 | 0.080 |
Why?
|
| Testis | 1 | 2012 | 620 | 0.080 |
Why?
|
| Melanoma, Experimental | 1 | 2011 | 381 | 0.080 |
Why?
|
| Phenotype | 3 | 2022 | 6503 | 0.080 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2019 | 709 | 0.080 |
Why?
|
| Antigen-Presenting Cells | 2 | 2020 | 285 | 0.080 |
Why?
|
| Interleukin-10 | 2 | 2008 | 479 | 0.080 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 1195 | 0.080 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2018 | 1385 | 0.070 |
Why?
|
| Ferric Compounds | 1 | 2008 | 77 | 0.070 |
Why?
|
| Clinical Trials as Topic | 4 | 2019 | 3840 | 0.070 |
Why?
|
| Antibodies, Neoplasm | 1 | 2008 | 273 | 0.070 |
Why?
|
| Leukocyte Common Antigens | 2 | 2005 | 191 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2024 | 4842 | 0.070 |
Why?
|
| Autoimmune Diseases | 1 | 2010 | 435 | 0.070 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2009 | 314 | 0.070 |
Why?
|
| Transcription Factors | 1 | 2020 | 5415 | 0.070 |
Why?
|
| In Vitro Techniques | 2 | 2007 | 1695 | 0.070 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2017 | 1905 | 0.070 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1992 | 1068 | 0.060 |
Why?
|
| Spinal Osteophytosis | 1 | 1985 | 7 | 0.060 |
Why?
|
| HLA-A Antigens | 1 | 2005 | 105 | 0.060 |
Why?
|
| Biomarkers, Tumor | 6 | 2020 | 10728 | 0.060 |
Why?
|
| Receptors, Chemokine | 1 | 2005 | 113 | 0.060 |
Why?
|
| HLA-A24 Antigen | 2 | 2017 | 12 | 0.060 |
Why?
|
| B-Lymphocytes | 3 | 2019 | 1420 | 0.060 |
Why?
|
| Blood Vessels | 1 | 1986 | 232 | 0.060 |
Why?
|
| Cell Line, Transformed | 1 | 2005 | 426 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2018 | 4965 | 0.060 |
Why?
|
| HIV Infections | 2 | 2016 | 2154 | 0.060 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2019 | 469 | 0.060 |
Why?
|
| Immunization, Passive | 1 | 2005 | 179 | 0.060 |
Why?
|
| Prognosis | 5 | 2020 | 22528 | 0.060 |
Why?
|
| Immunohistochemistry | 2 | 2014 | 7647 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2018 | 5417 | 0.060 |
Why?
|
| Immunoglobulin G | 1 | 2008 | 1101 | 0.060 |
Why?
|
| HEK293 Cells | 2 | 2019 | 1458 | 0.060 |
Why?
|
| Cervical Vertebrae | 1 | 1985 | 219 | 0.060 |
Why?
|
| Ecotype | 1 | 2023 | 9 | 0.060 |
Why?
|
| Adolescent | 3 | 2021 | 32691 | 0.060 |
Why?
|
| Mice, Knockout | 3 | 2019 | 5692 | 0.060 |
Why?
|
| Materials Testing | 2 | 2014 | 120 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 5582 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2020 | 2343 | 0.050 |
Why?
|
| Nanoparticles | 1 | 2008 | 589 | 0.050 |
Why?
|
| Interleukin-2 | 3 | 2002 | 889 | 0.050 |
Why?
|
| Kidney | 2 | 2022 | 2101 | 0.050 |
Why?
|
| Hydrogels | 1 | 2024 | 135 | 0.050 |
Why?
|
| Autoantigens | 1 | 2004 | 247 | 0.050 |
Why?
|
| Cell Adhesion | 1 | 2005 | 1023 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 2 | 2018 | 2419 | 0.050 |
Why?
|
| Transduction, Genetic | 3 | 2012 | 493 | 0.050 |
Why?
|
| Signal Transduction | 5 | 2020 | 12035 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2011 | 2363 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2022 | 184 | 0.050 |
Why?
|
| ErbB Receptors | 2 | 2021 | 2376 | 0.050 |
Why?
|
| Receptors, Histamine | 1 | 2021 | 8 | 0.050 |
Why?
|
| Mice, Transgenic | 2 | 2021 | 4198 | 0.050 |
Why?
|
| RNA Interference | 2 | 2018 | 1381 | 0.050 |
Why?
|
| RNA, Neoplasm | 1 | 2004 | 805 | 0.050 |
Why?
|
| Cell Count | 2 | 2014 | 509 | 0.050 |
Why?
|
| Biopsy | 2 | 2019 | 3490 | 0.050 |
Why?
|
| Safety | 1 | 2002 | 457 | 0.050 |
Why?
|
| HLA-A1 Antigen | 1 | 2020 | 9 | 0.050 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2021 | 45 | 0.050 |
Why?
|
| Antigen Presentation | 2 | 2017 | 286 | 0.050 |
Why?
|
| Isoenzymes | 2 | 2004 | 644 | 0.050 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 2020 | 17 | 0.050 |
Why?
|
| Genetic Therapy | 2 | 2019 | 1715 | 0.050 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2001 | 157 | 0.050 |
Why?
|
| Deglutition Disorders | 1 | 1985 | 487 | 0.050 |
Why?
|
| Myeloid Cells | 1 | 2022 | 274 | 0.040 |
Why?
|
| Cell Survival | 3 | 2014 | 3058 | 0.040 |
Why?
|
| Neoadjuvant Therapy | 1 | 2014 | 5246 | 0.040 |
Why?
|
| Neutrophil Activation | 1 | 2020 | 32 | 0.040 |
Why?
|
| Immunoglobulins | 1 | 2001 | 286 | 0.040 |
Why?
|
| Genes, MHC Class I | 1 | 2020 | 50 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2024 | 561 | 0.040 |
Why?
|
| Resorcinols | 1 | 2020 | 27 | 0.040 |
Why?
|
| Neoplasm Staging | 4 | 2021 | 14037 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor, Member 14 | 1 | 2019 | 6 | 0.040 |
Why?
|
| Gene Transfer Techniques | 2 | 2005 | 800 | 0.040 |
Why?
|
| Time Factors | 3 | 2021 | 12974 | 0.040 |
Why?
|
| Concanavalin A | 1 | 2019 | 63 | 0.040 |
Why?
|
| Galactosylceramides | 1 | 2019 | 25 | 0.040 |
Why?
|
| Stromal Cells | 1 | 2023 | 823 | 0.040 |
Why?
|
| Isoxazoles | 1 | 2020 | 81 | 0.040 |
Why?
|
| Immune Tolerance | 1 | 2021 | 434 | 0.040 |
Why?
|
| Palatine Tonsil | 1 | 2019 | 62 | 0.040 |
Why?
|
| Hydrodynamics | 1 | 2019 | 20 | 0.040 |
Why?
|
| Cell Movement | 2 | 2007 | 2468 | 0.040 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2020 | 186 | 0.040 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 1999 | 38 | 0.040 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2021 | 220 | 0.040 |
Why?
|
| Graft Survival | 1 | 2002 | 1076 | 0.040 |
Why?
|
| Myeloablative Agonists | 1 | 2021 | 388 | 0.040 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 31113 | 0.040 |
Why?
|
| GPI-Linked Proteins | 1 | 2019 | 233 | 0.040 |
Why?
|
| K562 Cells | 1 | 2019 | 344 | 0.040 |
Why?
|
| Glomerulonephritis | 1 | 2019 | 109 | 0.040 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2019 | 158 | 0.040 |
Why?
|
| Germinal Center | 1 | 2019 | 166 | 0.040 |
Why?
|
| Interferons | 1 | 2020 | 297 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2019 | 197 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2022 | 669 | 0.040 |
Why?
|
| Immune System | 1 | 2020 | 275 | 0.040 |
Why?
|
| Stress, Mechanical | 1 | 2019 | 271 | 0.040 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2002 | 517 | 0.040 |
Why?
|
| Vaccination | 1 | 2004 | 1113 | 0.040 |
Why?
|
| Biomarkers | 2 | 2019 | 5049 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2020 | 2618 | 0.040 |
Why?
|
| Histone Acetyltransferases | 1 | 2020 | 433 | 0.040 |
Why?
|
| Retroviridae | 3 | 2005 | 372 | 0.040 |
Why?
|
| RNA | 1 | 2022 | 1057 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2019 | 271 | 0.040 |
Why?
|
| Peritoneal Neoplasms | 1 | 2024 | 866 | 0.040 |
Why?
|
| Drug Therapy | 1 | 2018 | 205 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2020 | 632 | 0.040 |
Why?
|
| Peptide Fragments | 3 | 2013 | 1309 | 0.030 |
Why?
|
| Monocytes | 2 | 2013 | 784 | 0.030 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2020 | 605 | 0.030 |
Why?
|
| Italy | 1 | 2016 | 190 | 0.030 |
Why?
|
| Transcription, Genetic | 2 | 2019 | 3328 | 0.030 |
Why?
|
| Placenta | 1 | 2020 | 562 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2012 | 3707 | 0.030 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2018 | 396 | 0.030 |
Why?
|
| Ligands | 2 | 2013 | 1007 | 0.030 |
Why?
|
| Phagocytosis | 2 | 2008 | 293 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2022 | 1031 | 0.030 |
Why?
|
| Mutation | 3 | 2021 | 15922 | 0.030 |
Why?
|
| Acetylation | 1 | 2017 | 516 | 0.030 |
Why?
|
| Viral Load | 1 | 2018 | 481 | 0.030 |
Why?
|
| Necrosis | 2 | 2008 | 591 | 0.030 |
Why?
|
| Vaccines, DNA | 1 | 2016 | 109 | 0.030 |
Why?
|
| Gene Expression Profiling | 2 | 2020 | 5145 | 0.030 |
Why?
|
| Antioxidants | 1 | 2018 | 519 | 0.030 |
Why?
|
| RNA, Messenger | 4 | 1999 | 6344 | 0.030 |
Why?
|
| Skin | 1 | 2000 | 1280 | 0.030 |
Why?
|
| Radiation Tolerance | 1 | 2018 | 639 | 0.030 |
Why?
|
| Zebrafish | 1 | 2018 | 457 | 0.030 |
Why?
|
| Jurkat Cells | 2 | 2005 | 318 | 0.030 |
Why?
|
| DNA, Neoplasm | 2 | 1991 | 1958 | 0.030 |
Why?
|
| Equipment Design | 1 | 2018 | 1206 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 2 | 1998 | 1754 | 0.030 |
Why?
|
| Forecasting | 1 | 1997 | 699 | 0.030 |
Why?
|
| Antigens, Viral | 2 | 2013 | 495 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2017 | 386 | 0.030 |
Why?
|
| Signaling Lymphocytic Activation Molecule Family | 1 | 2014 | 7 | 0.030 |
Why?
|
| Receptors, Interleukin-1 | 1 | 1994 | 97 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2013 | 7055 | 0.030 |
Why?
|
| Virus Diseases | 1 | 1998 | 375 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2021 | 2855 | 0.030 |
Why?
|
| Dimethylpolysiloxanes | 1 | 2014 | 22 | 0.030 |
Why?
|
| Membranes, Artificial | 1 | 2014 | 39 | 0.030 |
Why?
|
| Bcl-2-Like Protein 11 | 1 | 2014 | 71 | 0.030 |
Why?
|
| Ions | 1 | 2014 | 57 | 0.030 |
Why?
|
| Protein Kinase C-delta | 1 | 2014 | 42 | 0.030 |
Why?
|
| Autophagy | 1 | 2020 | 905 | 0.030 |
Why?
|
| Chromones | 1 | 2014 | 121 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2020 | 2412 | 0.030 |
Why?
|
| Electronics | 1 | 2014 | 62 | 0.030 |
Why?
|
| Crystallization | 1 | 2014 | 128 | 0.030 |
Why?
|
| Recurrence | 1 | 2002 | 4878 | 0.030 |
Why?
|
| Pliability | 1 | 2013 | 13 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2010 | 1503 | 0.030 |
Why?
|
| Cytomegalovirus Infections | 2 | 1998 | 491 | 0.030 |
Why?
|
| Hydrolysis | 1 | 2014 | 236 | 0.030 |
Why?
|
| Down-Regulation | 2 | 2014 | 2087 | 0.030 |
Why?
|
| Lymphoma, Follicular | 1 | 2019 | 636 | 0.030 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2014 | 143 | 0.030 |
Why?
|
| Feeder Cells | 1 | 2013 | 11 | 0.030 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1994 | 217 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2014 | 354 | 0.030 |
Why?
|
| Nanotechnology | 1 | 2014 | 136 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2017 | 1108 | 0.030 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 1 | 2013 | 69 | 0.030 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2013 | 167 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2020 | 1576 | 0.030 |
Why?
|
| Flavonoids | 1 | 2014 | 199 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2014 | 604 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2021 | 1715 | 0.030 |
Why?
|
| Microscopy | 1 | 2014 | 189 | 0.030 |
Why?
|
| Endosomes | 1 | 2013 | 105 | 0.030 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2014 | 185 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2020 | 1243 | 0.030 |
Why?
|
| Temperature | 1 | 2014 | 534 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2014 | 425 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2014 | 547 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2020 | 2050 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 2 | 2008 | 3205 | 0.030 |
Why?
|
| Morpholines | 1 | 2014 | 296 | 0.030 |
Why?
|
| Interleukin-17 | 1 | 2014 | 251 | 0.030 |
Why?
|
| Genes, Immunoglobulin | 1 | 1992 | 85 | 0.020 |
Why?
|
| Breast | 1 | 2019 | 1370 | 0.020 |
Why?
|
| Transplantation Conditioning | 1 | 2021 | 2374 | 0.020 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 1991 | 135 | 0.020 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2013 | 1740 | 0.020 |
Why?
|
| Antigens, Viral, Tumor | 1 | 2011 | 72 | 0.020 |
Why?
|
| Epitope Mapping | 1 | 2011 | 110 | 0.020 |
Why?
|
| Young Adult | 2 | 2021 | 22241 | 0.020 |
Why?
|
| Blotting, Southern | 1 | 1991 | 453 | 0.020 |
Why?
|
| Biological Assay | 1 | 1992 | 176 | 0.020 |
Why?
|
| COS Cells | 1 | 2011 | 417 | 0.020 |
Why?
|
| Protein Transport | 1 | 2013 | 738 | 0.020 |
Why?
|
| Incidence | 1 | 2021 | 5814 | 0.020 |
Why?
|
| Kinetics | 1 | 2014 | 2206 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2014 | 1683 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2009 | 10409 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 4054 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2013 | 1250 | 0.020 |
Why?
|
| Reference Values | 1 | 1992 | 1127 | 0.020 |
Why?
|
| Genetic Vectors | 2 | 2005 | 1837 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 6255 | 0.020 |
Why?
|
| Transgenes | 1 | 2012 | 568 | 0.020 |
Why?
|
| Histones | 1 | 2017 | 1512 | 0.020 |
Why?
|
| Patient Care | 1 | 2011 | 148 | 0.020 |
Why?
|
| Immune Sera | 1 | 1989 | 137 | 0.020 |
Why?
|
| Ribonucleases | 1 | 1989 | 92 | 0.020 |
Why?
|
| Plasmids | 1 | 1991 | 923 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 1994 | 718 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2018 | 2112 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2010 | 887 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 1989 | 719 | 0.020 |
Why?
|
| Growth Substances | 1 | 1989 | 325 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1989 | 628 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2021 | 39968 | 0.020 |
Why?
|
| Imidazoles | 1 | 2014 | 1065 | 0.020 |
Why?
|
| Magnetics | 1 | 2008 | 98 | 0.020 |
Why?
|
| Gene Rearrangement | 1 | 1992 | 809 | 0.020 |
Why?
|
| Caspases | 1 | 2010 | 672 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2019 | 9278 | 0.020 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2008 | 107 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 2008 | 254 | 0.020 |
Why?
|
| Chemokine CCL19 | 1 | 2007 | 7 | 0.020 |
Why?
|
| Gene Expression | 2 | 2012 | 3606 | 0.020 |
Why?
|
| Pregnancy | 1 | 2020 | 7917 | 0.020 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2011 | 656 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2013 | 4532 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2013 | 2033 | 0.020 |
Why?
|
| Blood Physiological Phenomena | 1 | 1986 | 8 | 0.020 |
Why?
|
| Respiratory Insufficiency | 1 | 1990 | 342 | 0.020 |
Why?
|
| Sulfur Radioisotopes | 1 | 1986 | 29 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2013 | 1761 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2013 | 3048 | 0.020 |
Why?
|
| Wnt Proteins | 1 | 2008 | 384 | 0.020 |
Why?
|
| Gamma Rays | 1 | 2007 | 237 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1991 | 1623 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2013 | 6638 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2013 | 1944 | 0.020 |
Why?
|
| Basement Membrane | 1 | 1986 | 142 | 0.020 |
Why?
|
| Interleukin-12 | 1 | 2007 | 266 | 0.020 |
Why?
|
| Endothelium | 1 | 1986 | 154 | 0.020 |
Why?
|
| Methionine | 1 | 1986 | 170 | 0.020 |
Why?
|
| Culture Media | 1 | 1986 | 340 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2013 | 2440 | 0.020 |
Why?
|
| Hormones | 1 | 1986 | 284 | 0.020 |
Why?
|
| HLA-DR4 Antigen | 1 | 2004 | 9 | 0.010 |
Why?
|
| beta Catenin | 1 | 2008 | 689 | 0.010 |
Why?
|
| Glutamate Decarboxylase | 1 | 2004 | 47 | 0.010 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2004 | 195 | 0.010 |
Why?
|
| Binding Sites | 1 | 2008 | 2249 | 0.010 |
Why?
|
| Cytarabine | 1 | 1990 | 2015 | 0.010 |
Why?
|
| Receptors, Natural Killer Cell | 1 | 2002 | 16 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 5157 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2003 | 332 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 2008 | 2073 | 0.010 |
Why?
|
| Solubility | 1 | 2002 | 247 | 0.010 |
Why?
|
| Glycoproteins | 1 | 1986 | 775 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 2478 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2008 | 1557 | 0.010 |
Why?
|
| Models, Biological | 2 | 2003 | 3187 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 6192 | 0.010 |
Why?
|
| Patient Selection | 1 | 2008 | 2029 | 0.010 |
Why?
|
| Communicable Diseases | 1 | 2002 | 204 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2003 | 1469 | 0.010 |
Why?
|
| CD57 Antigens | 1 | 1999 | 22 | 0.010 |
Why?
|
| Genotype | 1 | 2008 | 4246 | 0.010 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 7 | 1 | 1999 | 3 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 4964 | 0.010 |
Why?
|
| Receptors, IgG | 1 | 1999 | 117 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 1999 | 257 | 0.010 |
Why?
|
| Hyaluronan Receptors | 1 | 1999 | 247 | 0.010 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 1999 | 238 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 1999 | 381 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1999 | 255 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 1992 | 15274 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2004 | 856 | 0.010 |
Why?
|
| Protein Binding | 1 | 2002 | 3472 | 0.010 |
Why?
|
| Antibodies | 1 | 1999 | 801 | 0.010 |
Why?
|
| CD8 Antigens | 1 | 1994 | 174 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 1994 | 286 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1999 | 2986 | 0.010 |
Why?
|
| Karyotyping | 1 | 1992 | 1064 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 1999 | 4969 | 0.010 |
Why?
|
| Herpesvirus 4, Human | 1 | 1992 | 959 | 0.000 |
Why?
|
| Translocation, Genetic | 1 | 1992 | 1286 | 0.000 |
Why?
|
| Acute Disease | 1 | 1990 | 2491 | 0.000 |
Why?
|
| Myocardium | 1 | 1990 | 1180 | 0.000 |
Why?
|
| Drug Administration Schedule | 1 | 1990 | 3534 | 0.000 |
Why?
|
| Intestinal Mucosa | 1 | 1990 | 1111 | 0.000 |
Why?
|
| Lung | 1 | 1990 | 3287 | 0.000 |
Why?
|